| Self‐reported financial burden of cancer care and its effect on physical and mental health‐related quality of life among US cancer survivors HP Kale, NV Carroll Cancer 122 (8), 283-289, 2016 | 391 | 2016 |
| Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended‐release oxycodone with abuse‐deterrent characteristics PM Coplan, H Kale, L Sandstrom, C Landau, HD Chilcoat Pharmacoepidemiology and drug safety 22 (12), 1274-1282, 2013 | 147 | 2013 |
| Reductions in reported deaths following the introduction of extended‐release oxycodone (OxyContin) with an abuse‐deterrent formulation NE Sessler, JM Downing, H Kale, HD Chilcoat, TF Baumgartner, ... Pharmacoepidemiology and drug safety 23 (12), 1238-1246, 2014 | 89 | 2014 |
| Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis S Corman, N Joshi, T Wert, H Kale, K Hill, AM Zeidan Clinical Lymphoma Myeloma and Leukemia 21 (2), e206-e211, 2021 | 18 | 2021 |
| Economic burden of renal cell carcinoma among older adults in the targeted therapy era HP Kale, PM D'Arcy, PA Nadpara, PW Slattum, AK Paul, NV Carroll Urologic Oncology: Seminars and Original Investigations 37 (6), 356. e19-356 …, 2019 | 17 | 2019 |
| A comparison of pharmacy dispensing channel use and adherence to specialty drugs among Medicare Part D beneficiaries HP Kale, AM Patel, NV Carroll Journal of managed care & specialty pharmacy 24 (4), 317-326, 2018 | 16 | 2018 |
| Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study A Aly, P Singh, B Korytowsky, YL Ling, HP Kale, HB Dastani, ... Neuro-Oncology Practice 7 (2), 164-175, 2020 | 10 | 2020 |
| Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: a large retrospective … N Joshi, H Kale, S Corman, T Wert, K Hill, AM Zeidan Clinical Lymphoma Myeloma and Leukemia 21 (3), e248-e254, 2021 | 9 | 2021 |
| Changes in healthcare resource use and costs in commercially insured insomnia patients initiating suvorexant HP Kale, ZP Qureshi, R Shah, R Khandker, M Botteman, W Meng, ... Advances in therapy 38 (10), 5221-5237, 2021 | 5 | 2021 |
| Impact of infliximab-dyyb (infliximab biosimilar) on clinical and patient-reported outcomes: 1-year follow-up results from an observational real-world study among patients with … B Abraham, B Eksteen, K Nedd, H Kale, D Patel, J Stephens, A Shelbaya, ... Advances in Therapy 39 (5), 2109-2127, 2022 | 4 | 2022 |
| Impact of hypomethylating agent use on hospital and emergency room visits, and predictors of early discontinuation in patients with higher-risk myelodysplastic syndromes AM Zeidan, N Joshi, H Kale, WJ Wang, S Corman, T Salimi, RS Epstein Clinical Lymphoma Myeloma and Leukemia 22 (9), 670-679, 2022 | 3 | 2022 |
| Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data NR Bhandari, HP Kale, NV Carroll, C McAdam-Marx, ST Ounpraseuth, ... Urologic Oncology: Seminars and Original Investigations 40 (7), 347. e17-347 …, 2022 | 3 | 2022 |
| Changes after reformulation of extended-release oxycodone in calls to US poison centers for oxycodone and heroin PM Coplan, H Kale, L Sandstrom, HD Chilcoat PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 21, 241-241, 2012 | 3 | 2012 |
| Trends in BRCA testing among patients diagnosed with breast cancer-a retrospective analysis of a United States commercial claims database from the PRIOR-1 study S Corman, H Kale, P Shah, G Adeboyeje CANCER RESEARCH 81 (4), 2021 | 2 | 2021 |
| Use of BRCA testing among patients diagnosed with pancreatic cancer: Analysis of commercial claims database in the United States. G Adeboyeje, P Shah, S Corman, H Kale Journal of Clinical Oncology 38 (29_suppl), 291-291, 2020 | 2 | 2020 |
| Effects of reformulated OxyContin® on opioid abuse in the National Poison Data System P Coplan, H Kale, L Sandstom, H Chilcoat The Journal of Pain 13 (4), S83, 2012 | 2 | 2012 |
| Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes AM Zeidan, N Joshi, H Kale, WJ Wang, S Corman, K Hill, T Salimi, ... Age (ref:≥ 80) 66 (70), 0.112, 2021 | 1 | 2021 |
| S0725 Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-Up Results From an Observational Real World Study Among … BP Abraham, B Eksteen, K Nedd, HP Kale, D Patel, J Stephens, ... Official journal of the American College of Gastroenterology| ACG 115, S364, 2020 | 1 | 2020 |
| Routes of administration and frequency of abuse of OxyContin® and immediate-release oxycodone in a rural Kentucky county following introduction of reformulated OxyContin … JR Havens, A DeVeaugh-Geiss, C Leukefeld, H Kale, P Coplan, ... Drug and Alcohol Dependence 100 (146), e138, 2015 | 1 | 2015 |
| Reductions in fatalities following introduction of a reformulated opioid with abuse-deterrent properties NE Sessler, JM Downing, HP Kale, B Harding, HD Chilcoat, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 22, 256-256, 2013 | 1 | 2013 |
